Health Implications of Elevated PFAS Levels in Lancashire Residents' Blood
Residents near a chemical plant in Thornton-Cleveleys, Lancashire, have recently been found to have elevated levels of PFAS (per- and polyfluoroalkyl substances), often referred to as 'forever chemicals.' This discovery has prompted concerns regarding the potential health implications for these individuals. Research spanning over a decade has revealed that while the PFAS levels in Thornton-Cleveleys are higher than those typically found in the general population, they align with levels observed in other exposed communities. However, they are not the highest levels recorded, with some areas in Sweden reporting even greater concentrations.
Blood tests can confirm exposure to PFAS, and the specific patterns of these chemicals can provide insights into their sources. Nonetheless, it is important to note that such tests do not predict whether an individual will develop health issues. Numerous studies have established connections between certain PFAS and adverse health outcomes, including alterations in cholesterol levels, reduced vaccine efficacy in children, lower birth weights, and an increased risk of kidney and testicular cancers, particularly associated with PFOA, a type of PFAS found in the Thornton-Cleveleys area.
The risk associated with these health outcomes tends to be small for individuals but becomes apparent when examining larger populations with varying exposure levels. A notable case is that of Ronneby in southern Sweden, where high PFAS levels were detected in drinking water due to contamination from firefighting foam. This situation allowed researchers to track health outcomes over time, revealing the complexities of linking exposure to individual health effects. The Swedish Supreme Court recognized that elevated PFAS levels in blood, combined with observed health issues, constituted a form of personal injury.
Time is a critical factor in understanding PFAS exposure. The levels detected today may reflect exposure that began years prior and may still be ongoing. Researchers are investigating whether certain medications can expedite the elimination of PFAS from the body, but such treatments remain experimental and are not recommended for those with moderate exposure levels like those reported in Thornton-Cleveleys.
PFAS are particularly challenging pollutants due to their persistence in the environment and their mobility in water, allowing them to spread across large areas. The European Commission has estimated that the cost of treating PFAS-contaminated water in Europe could exceed €1 trillion by 2050. As regulations tighten on older PFAS, companies are shifting to similar chemicals, many of which also exhibit long-term persistence and whose health impacts are not yet fully understood. This has led to discussions in Europe about regulating PFAS as a group rather than individually.
The lessons learned from communities like Ronneby and now Thornton-Cleveleys underscore the importance of halting exposure to PFAS and holding responsible parties accountable. While blood tests can indicate exposure, they should not be misconstrued as definitive predictors of disease. The focus must remain on reducing exposure and understanding the broader implications of PFAS contamination.




